
    
      Primary Objective:

      - To assess the efficacy of cytoreductive surgery with gemcitabine HIPEC followed by
      postoperative systemic chemotherapy with dacarbazine in subjects with locally recurrent
      uterine LMS.

      Secondary Objectives:

        -  To assess the safety of cytoreductive surgery with gemcitabine HIPEC in subjects with
           locally recurrent uterine LMS.

        -  To assess the 6 month and 12 month intraabdominal relapse free survival in subjects with
           locally recurrent uterine LMS

        -  To determine quality of life prior to therapy (within 28 days prior to surgery with
           HIPEC), 4 to 6 weeks after surgery with HIPEC, and then at Cycle
    
  